The Effect Of Celecoxib On The Perioperative Inflammatory Response In Colon Cancer Patients - A Double-Blind Placebo-Controlled Trial
The proposed study aims to investigate how the administration of a drug known to reduce inflammation in humans, Celecoxib, will effect the peri-operative inflammatory response of a patient undergoing primary tumor resection surgery for colon cancer. The proposed project is an exploratory study, and will use data from blood samples and tumor samples to attempt to elucidate the immune and inflammatory response in colon cancer patients undergoing primary resection of their tumors.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Celecoxib
Ages Eligible For Study:
- Colon cancer patients with no evidence of metastasis in distant organs (i.e., TNM stage I-III), who are - between 18 and 75 years old, - have a body mass index (BMI) between 18 and 35 kg/m^2, - and are eligible for laparoscopically-assisted colectomy for primary tumor resection. - Patients must have the ability to understand and the willingness to sign a written informed consent document.